AI assistant
Vivesto — AGM Information 2014
Sep 1, 2014
3124_rns_2014-09-01_2e54c4b3-f4d0-44c0-9904-82cad84ce8f1.pdf
AGM Information
Open in viewerOpens in your device viewer
PRESS RELEASE
Correction of notice regarding notice of Annual General Meeting
In the English translation of the notice, the suggestion for re-election of the board should read Joel Citron, Horst Domdey, Alexander Kotsinas, Bo Cederstrand and Julian Aleksov, and election of Hans Sundin.
For more information, please contact: Mikael Widell, Vice President Communications Mobile: +46 70 311 99 60 E-mail: mikael.[email protected]
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company€s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company€s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).
Information is also available at twitter.com/oasmia
€Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 13.30, CET on September 1, 2014.•
2014-09-01